Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 56 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Corneal Cross-Linking Clear all
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 26, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

Collagen Cross-linking in Keratoconus

NCT03760432
View directory record Official record
Conditions
Keratoconus
Interventions
Laser Custom Corneal Collagen Cross-Linking
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 26, 2026, 5:03 PM EDT
Completed No phase listed Observational

Combined CXL//UV and PRK or LASIK in Forme Fruste Keratoconus or Eyes With Potential Risk of Ectasia

NCT01726283
View directory record Official record
Conditions
Fruste Keratoconus, Risk of Ectasia
Interventions
Corneal Cross-Linking, Riboflavin
Device · Drug
Lead sponsor
Cxlusa
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Scottsdale, Arizona • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 26, 2026, 5:03 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

fMRI and IVCM Cornea Microscopy of CXL in Keratoconus

NCT04439552
View directory record Official record
Conditions
Pain, Postoperative, Pain, Chronic, Pain, Acute, Surgical Injury, Surgical Wound, Cornea Injury, Cornea, Keratoconus
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 26, 2026, 5:03 PM EDT
Recruiting Phase 4 Interventional

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

NCT07629557
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin Ophthalmic Solutions, UV-A Irradiation System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
13 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Westerville, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 26, 2026, 5:03 PM EDT
Not listed Phase 2Phase 3 Interventional

Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs

NCT01081561
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Yaron S. Rabinowitz M.D.
Other
Eligibility
21 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Oct 26, 2026, 5:03 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety and Effectiveness of the PXL-Platinum 330 System

NCT04401865
View directory record Official record
Conditions
Corneal Ectasia, Keratoconus, Pellucid Marginal Corneal Degeneration
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Colorado Eye Consultants/Cornea Consultants of Colorado
Industry
Eligibility
8 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Littleton, Colorado • Highland Park, Illinois • Brecksville, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Oct 26, 2026, 5:03 PM EDT
Completed Phase 3 Interventional Results available

Cross-linking for Corneal Ulcers Treatment Trial

NCT02570321
View directory record Official record
Conditions
Corneal Ulcer, Infectious Keratitis, Bacterial Ulcer, Fungal Ulcer
Interventions
Corneal Cross-linking, Anti Fungal Drug
Procedure · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 26, 2026, 5:03 PM EDT
Not listed Phase 3 Interventional

Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia

NCT03080077
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, Epi-Off
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
10 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Oct 26, 2026, 5:03 PM EDT
Not listed Phase 2 Interventional

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus

NCT00925327
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
Corneal collagen cross-linking with riboflavin/UVA light
Other
Lead sponsor
Peschke Meditrade, GmbH
Industry
Eligibility
6 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 22, 2009 · Synced Oct 26, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

Safety Study of the VEGA UV-A System to Treat Keratoconus

NCT01190306
View directory record Official record
Conditions
Keratoconus
Interventions
The VEGA UV-A Illumination System, Riboflavin
Device · Drug
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
12 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Phoenix, Arizona • Atlanta, Georgia • Bloomington, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 26, 2026, 5:03 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01344187
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin solution, placebo solution, KXL System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Irvine, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2021 · Synced Oct 26, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

Compassionate Use Study of Epi-ON Corneal Collagen Crosslinking Performed Using UVA Exposure on Eyes With Ectatic Corneal Diseases for Subjects With Down Syndrome

NCT07135167
View directory record Official record
Conditions
Down Syndrome (DS), Keratoconus, Pellucid Marginal Degeneration, Forme Fruste Keratoconus (FFK)
Interventions
Epi-ON corneal cross-linking (CXL)
Combination Product
Lead sponsor
Woolfson Eye Institute
Other
Eligibility
8 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
12
States / cities
Atlanta, Georgia • Canton, Georgia • Cumming, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Oct 26, 2026, 5:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Ocular Bandage Gel (OBG) Pivotal Trial in Patients Undergoing Photorefractive Keratectomy ("PRK")

NCT03938883
View directory record Official record
Conditions
Ophthalmology, Photorefractive Keratectomy ("PRK"), Laser Assisted Surgery, Refractive Surgery
Interventions
Ocular Bandage Gel (OBG), Bandage Contact Lens (BCL)
Device
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
22 Years to 50 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Oct 26, 2026, 5:03 PM EDT
Terminated Not applicable Interventional Results available

Cross Linking for Treatment of Corneal Infection

NCT00912509
View directory record Official record
Conditions
Infectious Keratitis
Interventions
riboflavin, UVX Light
Drug · Device
Lead sponsor
Price Vision Group
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Nov 22, 2017 · Synced Oct 26, 2026, 5:03 PM EDT
Not listed Phase 2Phase 3 Interventional Accepts healthy volunteers

Treatment of Keratoconus Using Collagen Cross-Linking

NCT00841386
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin-5-phosphate, Sham cross-linking
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
16 Years to 35 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
2
States / cities
Amherst, New York • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2009 · Synced Oct 26, 2026, 5:03 PM EDT
Not listed Phase 3 Interventional

The Effects of Corneal Collagen Cross-linking

NCT01708538
View directory record Official record
Conditions
Corneal Ectasia Disorders Including Keratoconus
Interventions
CXL
Drug
Lead sponsor
Rush Eye Associates
Other
Eligibility
10 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 26, 2026, 5:03 PM EDT
Completed Phase 2Phase 3 Interventional

Corneal Collagen Cross-Linking for the Treatment of Progressive Keratoconus and Corneal Ectasia

NCT00567671
View directory record Official record
Conditions
Progressive Keratoconus, Corneal Ectasia
Interventions
Corneal collagen, Sham comparator
Procedure
Lead sponsor
Emory University
Other
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2010 · Synced Oct 26, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection

NCT02068430
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Riboflavin 0.1%, UV-X™ Illumination System
Drug · Other
Lead sponsor
Stephen Trokel
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 26, 2026, 5:03 PM EDT
Not listed Phase 3 Interventional

Corneal Collagen Cross-Linking (CXL) Performed With "Epi-ON" Versus "Epi-OFF" in Eyes With Keratoconus and Other Corneal Ectatic Disorders

NCT03858036
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Ricrolin+, VEGA UV-A system
Drug · Device
Lead sponsor
Center for Sight, Sacramento, CA
Other
Eligibility
12 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2019 · Synced Oct 26, 2026, 5:03 PM EDT
Recruiting Phase 2 Interventional

ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty

NCT06753916
View directory record Official record
Conditions
Corneal Transplant Failure
Interventions
Corneal Donor Tissue with Cross Linking, Corneal Donor Tissue without Cross Linking
Procedure
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
12
States / cities
Irvine, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 26, 2026, 5:03 PM EDT
Terminated Phase 2 Interventional Results available

Collagen Cross-Linking With Ultraviolet-A in Asymmetric Corneas

NCT03029104
View directory record Official record
Conditions
Keratoconus, Corneal Diseases, Eye Diseases, Photosensitizing Agents
Interventions
CXLO Corneal Strengthening Solution and UVA Illumination Device
Combination Product
Lead sponsor
Cxlusa
Industry
Eligibility
8 Years and older
Enrollment
2,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
9
States / cities
Scottsdale, Arizona • San Francisco, California • Littleton, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Oct 26, 2026, 5:03 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

UVA-Riboflavin Crosslinking Treatment of Corneal Ectasia

NCT01325298
View directory record Official record
Conditions
Keratoconus, Ectasia, Corneal Ectasia
Interventions
UV-X Light, Riboflavin
Device · Drug
Lead sponsor
Mercy Center for Corrective Eye Surgery
Other
Eligibility
14 Years to 55 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
McHenry, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 29, 2011 · Synced Oct 26, 2026, 5:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety & Effectiveness of the PXL-Platinum 330 System for CXL Using Riboflavin Solution

NCT04667572
View directory record Official record
Conditions
Keratoconus, Pellucid Marginal Corneal Degeneration, Corneal Degeneration, Corneal Ectasia
Interventions
PXL-330 Platinum device for crosslinking with Peschke riboflavin solution
Combination Product
Lead sponsor
Cornea Associates of Texas
Other
Eligibility
8 Years and older
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 26, 2026, 5:03 PM EDT